Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15609314 | 1.00 | CTSK (0.45) | CTSKCASRKDM4DGABRB1GABRB2 | |
| SCHEMBL505937 | 0.88 | CTSK (0.48) | CTSKGABRB1GABRB2CTSSGPR139 | |
| SCHEMBL320557 | 0.88 | CTSK (0.48) | CTSKGABRB1GABRB2CTSSGPR139 | |
| SCHEMBL30458165 | 0.87 | NPSR1 (0.47) | CTSKCYP4F2CYP4A11 | |
| SCHEMBL4841362 | 0.83 | ROCK2 (0.45) | CTSKCASRKDM4DGABRB1GABRB2 | |
| SCHEMBL4841357 | 0.83 | ROCK2 (0.45) | CTSKCASRKDM4DGABRB1GABRB2 | |
| SCHEMBL10070329 | 0.83 | CASR (0.44) | CTSKCASRKDM4DGABRB1GABRB2 | |
| SCHEMBL1725645 | 0.83 | CTSK (0.45) | CTSK | |
| SCHEMBL3982091 | 0.83 | CTSK (0.45) | CTSK | |
| SCHEMBL1269661 | 0.83 | CTSK (0.45) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848610-B1 | Inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-3048099-A2 | INHIBITORS OF KINASE ACTIVITY | YM BioSciences Australia Pty Ltd (AU) | 2016-07-27 | — | — | EP | disclosed |
| US-9029386-B2 | Pyridine derivatives useful as kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2848610-A1 | Inhibitors of kinase activity | YM BioSciences Australia Pty Ltd (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-05-30 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| EP-2099774-A1 | INHIBITORS OF KINASE ACTIVITY | Cytopia Research Pty Ltd (AU) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008058341-A1 | INHIBITORS OF KINASE ACTIVITY | CYTOPIA RESEARCH PTY LTD (AU) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | CTSK 472/4885CASR 1221/4885KDM4D 1708/4885 |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | CTSK 472/4885CASR 1221/4885KDM4D 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.